FIMECS
@fimecs.com
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
FIMECS's Company Logos
FIMECS's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FF0066
Rose
255, 0, 102
336, 100, 50
0, 100, 60, 0
#C2C2C2
Silver
194, 194, 194
0, 0, 76
0, 0, 0, 24
#10253F
Blue Zodiac
16, 37, 63
213, 59, 15
75, 41, 0, 75
About FIMECS
Fimecs is a Japanese company that specializes in the research and development of novel pharmaceuticals based on protein degradation induction. With a mission to revolutionize the medical industry, Fimecs focuses on developing cutting-edge technologies and business models to deliver innovative solutions. The company was established in January 2018 in Fujisawa City, Kanagawa Prefecture.
Led by CEO Yusuke Fusen, Fimecs has a dedicated team of 9+25 individuals. They possess a capital of 100 million yen as of December 2022. Fimecs has achieved several significant milestones in its journey.
They acquired the rights to compounds and associated target protein degradation induction agents related to IRAK-M and TRIB1 from Takeda Pharmaceutical Co., Ltd. The company also entered into joint research agreements with renowned institutions such as the National Institute of Genetics and Kyoto University to advance their drug discovery efforts. Additionally, Fimecs' expertise in proteomics has led to collaborations with prominent organizations like Tokyo University and Astellas Pharma Co., Ltd., focused on protein degradation induction agents.
Driven by a commitment to excellence, Fimecs aims to pave the way for groundbreaking advancements in medicine and continuously contribute to the betterment of society
Company type
Privately Held
Year founded
2018
Company size
11-50 employees
